Polymeric IgA Antibody Production via Coexpression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack the ability to artificially produce polymeric IgA-type antibodies on an industrial scale and convert IgG-type antibodies into high-functionality IgA-type antibodies, with limited understanding of the biological significance of polymeric IgA and poor yield of dimeric IgA production.
Innovation Solution
A method involving genetic recombination to produce polymeric IgA-type recombinant antibodies by coexpressing IgA-type antibody heavy-chain, light-chain, J-chain, and secretory component proteins in a single cell, using a CHO YA7 cell line and specific cis-elements to enhance expression and secretion, resulting in a higher content of tetrameric forms with improved antigen-binding activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If dimeric IgA is produced artificially, then some antibody production is achieved, but the yield is poor
Solution Approach 1:
The patent merges the expression of multiple proteins (IgA heavy chain, IgA light chain, J chain, and secretory component) within a single cell system. This combination enables the formation of polymeric IgA structures (dimers, trimers, tetramers) directly during production, significantly improving yield compared to conventional separate expression methods
Solution Approach 2:
The patent modifies the constant region amino acid sequence of the IgA heavy chain, specifically at position 458, to enhance polymeric structure formation. This parameter change in the protein sequence promotes proper folding and assembly of polymeric IgA, improving both yield and structural integrity
2Reliability
If IgG-type antibodies are converted to IgA-type, then antibody functionality is improved for mucosal defense, but the conversion technology is not established
Solution Approach 1:
The patent segments the antibody production process into distinct functional components: IgA heavy chain expression, IgA light chain expression, J chain expression, and secretory component expression. Each component can be independently optimized and then assembled to form functional polymeric IgA antibodies with enhanced mucosal defense capabilities
Solution Approach 2:
The J chain acts as an intermediary protein that facilitates the assembly and stabilization of polymeric IgA structures. The secretory component serves as another intermediary that promotes proper folding and secretion of polymeric IgA, enabling successful conversion from IgG-type to IgA-type functionality
3Reliability
If polymeric IgA is produced, then antigen-binding activity is enhanced, but the production method is not known
Solution Approach 1:
The patent combines multiple antibody chains and accessory proteins (J chain and secretory component) in a single expression system, enabling the spontaneous assembly of polymeric IgA structures with enhanced antigen-binding activity. This merged approach eliminates the need for complex post-production assembly steps
Solution Approach 2:
The patent creates a composite protein structure consisting of multiple IgA monomers linked through J chains and secretory components. This composite polymeric structure provides enhanced antigen-binding activity through multiple binding sites while maintaining the manufacturing feasibility through a unified expression system
Data Source
AI summary
Provided are: a polymeric IgA-type recombinant antibody; a medicine containing this polymeric IgA-type recombinant antibody as an active ingredient; a method for producing this polymeric IgA type antibody, the method including the step of coexpressing an IgA-type antibody heavy-chain protein, an antibody light-chain protein, an antibody J-chain protein, and a secretory component protein within a single cell; and a method for improving the antigen-binding activity or neutralizing activity of this antibody, the method including the step of making an antibody into a polymeric IgA-type.